Medibio (ASX:MEB) has announced the appointment of Dr Thomas Young as executive director of the company in addition to his current position as chief executive officer.
The company said Dr Young has demonstrated exceptional leadership skills and invaluable industry knowledge in his role as CEO during the short period and the company looks forward to him leading the its management going forward.
Medibio also announced the resignation of Melanie Leydin as a non-executive director. Stephen Buckley has been appointed company secretary. He will succeed Mathew Watkins,
David Trimboli, the non-executive chair of Medibio, said, “We are excited to welcome Dr Tom Young onto the Medibio Board. Tom’s executive position within the Company, his knowledge of the US industry and most importantly his proven track record in commercialising medical based technologies ensures the Board restructure at the company is now complete and we can focus on developing our technology and commercialising. The Board would like to thank Melanie and Mathew for all of their work and cooperation during this restructuring process.”